Avoro Capital Urges Acceleron Shareholders Not to Tender Into Merck's Inadequate OfferBusiness Wire • 11/17/21
Avoro Capital Releases Presentation Detailing Why Acceleron Shareholders Should Not Tender Into Merck's Inadequate OfferBusiness Wire • 11/09/21
SHAREHOLDER ALERT: WeissLaw LLP Reminds DWSN, PAE, XLRN, and FLXN Shareholders About Its Ongoing InvestigationsPRNewsWire • 11/02/21
Earnings Preview: Acceleron Pharma (XLRN) Q3 Earnings Expected to DeclineZacks Investment Research • 10/28/21
SHAREHOLDER ALERT: WeissLaw LLP Reminds MDP, GWB, XLRN and HFC Shareholders About Its Ongoing InvestigationsPRNewsWire • 10/22/21
Darwin Global Urges Acceleron Shareholders Not to Tender Their Shares to MerckBusiness Wire • 10/20/21
ACCELERON PHARMA ALERT: Investors Should Contact Bragar Eagel & Squire, P.C. Over Tender Offer for XLRN SharesBusiness Wire • 10/18/21
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Acceleron Pharma Inc. - XLRNPRNewsWire • 10/13/21
Holocene Advisors Believes Merck's Proposed Offer of $180 Per Share for Acceleron Significantly Undervalues CompanyBusiness Wire • 10/13/21
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Merger of Acceleron Pharma Inc. with Merck & Co., Inc.Newsfile Corp • 10/04/21
ACCELERON INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acceleron Pharma Inc. - XLRNBusiness Wire • 10/01/21